This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Friedman, P. N. Articles by Siegall, C. B. Search for Related Content PubMed PubMed Citation Articles by Friedman, P. N. Articles by Siegall, C. B.

BR96 sFv-PE40, a Potent Single-Chain Immunotoxin That Selectively Kills Carcinoma Cells

Bristol-Myers Squibb, Pharmaceutical Research Institute, Cellular and Molecular Biology Department [P. N. F., S. J. M., S. L. G., D. C., J. P. B., C. B. S.], and Experimental Therapeutics, Wallingford, Connecticut 06492

¹ To whom requests for reprints should be addressed, at Bristol-Myers Squibb Pharmaceutical Research Institute, Molecular Immunology Department, 3005 First Avenue, Seattle, WA 98121.

We have constructed a single-chain immunotoxin composed of the carcinoma-reactive antibody BR96 and a truncated form of Pseudomonas exotoxin. The chimeric molecule, BR96 sFv-PE40, was expressed in Escherichia coli and localized to the inclusion bodies. We purified and identified two species of BR96 sFv-PE40, monomers and aggregates. The monomeric form was able to bind well to the BR96 antigen, a Lewis^y-related antigen, while the aggregate was not. The binding affinity of the monomeric recombinant immunotoxin was 5-fold less than intact BR96 IgG, and its specificity for the BR96 antigen was confirmed by competition analysis. Monomeric BR96 sFv-PE40 was found to be extremely cytotoxic against cancer cells displaying the BR96 antigen. The cytotoxicity of the fusion protein correlates directly with antigen density on the tumor cell lines tested. The breast carcinoma cell line MCF-7, which has the highest density of BR96 antigen, was the most sensitive to BR96 sFv-PE40, with a concentration producing 50% protein synthesis inhibition of 5 pM. BR96 sFv-PE40 was found to have a t in serum of 28.5 min in athymic mice, compared to that of the chemical conjugate, chiBR96-LysPE40, which was 54 min. These data indicate that the single-chain immunotoxin BR96 sFv-PE40 is a potent inhibitor of protein synthesis in target cell lines and may be an effective agent for the treatment of cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8/ 5/92. Accepted 10/29/92.

This article has been cited by other articles:

				C. J. Henry, M. S. Buss, I. Hellstrom, K. E. Hellstrom, W. G. Brewer, J. N. Bryan, and C. B. Siegall Clinical Evaluation of BR96 sFv-PE40 Immunotoxin Therapy in Canine Models of Spontaneously Occurring Invasive Carcinoma Clin. Cancer Res., January 15, 2005; 11(2): 751 - 755. [Abstract] [Full Text] [PDF]

				J. A. Posey, M. B. Khazaeli, M. A. Bookman, A. Nowrouzi, W. E. Grizzle, J. Thornton, D. E. Carey, J. M. Lorenz, A. P. Sing, C. B. Siegall, et al. A Phase I Trial of the Single-Chain Immunotoxin SGN-10 (BR96 sFv-PE40) in Patients with Advanced Solid Tumors Clin. Cancer Res., October 1, 2002; 8(10): 3092 - 3099. [Abstract] [Full Text] [PDF]

				H.G. Haggerty, W.A. Warner, C.R. Comereski, W.M. Peden, L.E. Mezza, B.D. Damle, C.B. Siegall, and T.J. Davidson BR96 sFv-PE40 Immunotoxin: Nonclinical Safety Assessment Toxicol Pathol, January 1, 1999; 27(1): 87 - 94. [Abstract] [PDF]

				J. A. Francisco, S. L. Gawlak, and C. B. Siegall Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1 J. Biol. Chem., September 26, 1997; 272(39): 24165 - 24169. [Abstract] [Full Text] [PDF]

				C. B. Siegall, S. S. Bacus, G. D. Plowman, B. Mixan, D. Chace, D. M. Chin, A. Goetze, J. M. Green, I. Hellström, and H. P. Fell HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein J. Biol. Chem., March 31, 1995; 270(13): 7625 - 7630. [Abstract] [Full Text] [PDF]